Immune checkpoint inhibitors (ICPis) are emerging anti-tumor drugs

with endocrine adverse reactions as its most common adverse drug reactions

and mainly involves multiple endocrine glands

such as glands of thyroid

pituitary

adrenal and pancreas

leading to endocrine dysfunction. If its emergencies can not be correctly identified and prevented in the early stage

it may be life-threatening. Although a number of relevant guidelines/consensuses have been published at home and abroad

there is no consensus on the diagnosis and treatment process of endocrine adverse reactions caused by ICPis in China. In order to standardize and improve the clinical diagnosis and treatment level of relevant departments

we have reviewed and analyzed a number of domestic and international expert consensuses and clinical studies

and formulated this consensus based on integration of the opinions of oncology

endocrinology and nursing experts.